K Malmqvist

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi Regression of left ventricular hypertrophy in human hypertension with irbesartan
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Sweden
    J Hypertens 19:1167-76. 2001
  2. ncbi Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide
    K Malmqvist
    Karolinska Institutet Danderyd Hospital, Division of Internal Medicine, Sweden
    Am J Hypertens 13:504-11. 2000
  3. ncbi Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy
    Karin Malmqvist
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    J Hypertens 20:1563-9. 2002
  4. ncbi Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    J Intern Med 252:430-9. 2002
  5. ncbi Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA)
    Karin Malmqvist
    Division of Internal Medicine, Section of Cardiology, Karolinska Institutet Danderyd Hospital, S 182 88 Stockholm, Sweden
    Am J Cardiol 90:1107-12. 2002
  6. ncbi Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet, Danderyd Hospital, Sweden
    Blood Press 10:101-10. 2001
  7. ncbi Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet, Danderyd Hospital, Danderyd, Sweden
    Clin Physiol 21:196-207. 2001
  8. ncbi Left ventricular mass is not related to insulin sensitivity in never-treated primary hypertension
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Sweden
    J Hypertens 19:311-7. 2001
  9. ncbi Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study
    D Mörtsell
    Division of Cardiology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
    J Intern Med 261:472-9. 2007
  10. ncbi Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study
    K Malmqvist
    Karolinska Institutet, Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
    J Hum Hypertens 21:956-65. 2007

Detail Information

Publications25

  1. ncbi Regression of left ventricular hypertrophy in human hypertension with irbesartan
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Sweden
    J Hypertens 19:1167-76. 2001
    ....
  2. ncbi Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide
    K Malmqvist
    Karolinska Institutet Danderyd Hospital, Division of Internal Medicine, Sweden
    Am J Hypertens 13:504-11. 2000
    ..001). In conclusion, candesartan cilexetil reduced blood pressure more effectively and was better tolerated than enalapril or HCTZ in women with mild to moderate hypertension...
  3. ncbi Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy
    Karin Malmqvist
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    J Hypertens 20:1563-9. 2002
    ..We investigated whether concentric LV hypertrophy is associated with activation of the vascular endothelium, as assessed by measurements of soluble cell adhesion molecules...
  4. ncbi Relationships between left ventricular mass and the renin-angiotensin system, catecholamines, insulin and leptin
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    J Intern Med 252:430-9. 2002
    ..We studied associations between LV mass and markers of the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, glucose homeostasis and leptin...
  5. ncbi Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA)
    Karin Malmqvist
    Division of Internal Medicine, Section of Cardiology, Karolinska Institutet Danderyd Hospital, S 182 88 Stockholm, Sweden
    Am J Cardiol 90:1107-12. 2002
    ....
  6. ncbi Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet, Danderyd Hospital, Sweden
    Blood Press 10:101-10. 2001
    ..We compared the effects of captopril and metoprolol on the regression of LV mass and the relation to insulin sensitivity...
  7. ncbi Evaluation of various electrocardiographic criteria for left ventricular hypertrophy in patients with stable angina pectoris: influence of using modified limb electrodes
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet, Danderyd Hospital, Danderyd, Sweden
    Clin Physiol 21:196-207. 2001
    ..Electrocardiography (ECG) criteria for LVH, when using ECG with modified limb electrode positions, has not been validated in patients with angina pectoris...
  8. ncbi Left ventricular mass is not related to insulin sensitivity in never-treated primary hypertension
    K Malmqvist
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Sweden
    J Hypertens 19:311-7. 2001
    ..Insulin has been suggested to promote myocardial cell growth and the development of left ventricular (LV) hypertrophy. This study examines the possible relationship between LV mass and insulin sensitivity...
  9. ncbi Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study
    D Mörtsell
    Division of Cardiology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
    J Intern Med 261:472-9. 2007
    ..We wished to examine whether an angiotensin receptor blocker (ARB) would influence structural vascular changes beyond the effects of blood pressure reduction...
  10. ncbi Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study
    K Malmqvist
    Karolinska Institutet, Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden
    J Hum Hypertens 21:956-65. 2007
    ..Echocardiographic characterization of the geometry in hypertension-induced LV hypertrophy might become an important step in the selection of optimal antihypertensive therapy...
  11. ncbi Blood pressure and left ventricular geometric pattern determine diastolic function in hypertensive myocardial hypertrophy
    R Müller-Brunotte
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    J Hum Hypertens 17:841-9. 2003
    ..Age and blood pressure are the most important factors to determine the E/A-ratio and E-dec, whereas LV geometry and blood pressure are most important when IVRT is used. AV-LA/AV-mean may not be useful in hypertensive LV hypertrophy...
  12. ncbi Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy
    Richard Müller-Brunotte
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    J Hypertens 23:633-40. 2005
    ..This study examines the effects of 48 weeks of double-blind treatment with the AT1 receptor blocker irbesartan and the beta-blocker atenolol on diastolic function...
  13. ncbi Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment
    Ulrika Liljedahl
    Department of Medical Sciences, Uppsala University, Sweden
    J Hypertens 22:2321-8. 2004
    ....
  14. ncbi Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)
    Par Hallberg
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    Clin Cardiol 27:169-73. 2004
    ..The TGF-beta1 G + 915C polymorphism is associated with interindividual variation in TGF-beta1 production. No study has yet determined the impact of this polymorphism on the response to antihypertensive treatment...
  15. ncbi Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation
    Richard Müller-Brunotte
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    Am J Hypertens 19:927-36. 2006
    ..Abnormal diastolic function is common in hypertensive left ventricular hypertrophy (LVH). Early identification and treatment may prevent future cardiovascular events...
  16. ncbi Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial
    Lisa Kurland
    Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Am J Hypertens 17:8-13. 2004
    ..Our aim was to determine whether specific single nucleotide polymorphisms (SNPs) in RAAS genes were related to the blood pressure (BP) lowering effect of antihypertensive treatment...
  17. ncbi Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)
    Karin Malmqvist
    Division of Internal Medicine, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
    J Cardiovasc Pharmacol 42:719-26. 2003
    ..Thus, the renin-angiotensin aldosterone system appears to be an important non-hemodynamic factor in the regulation of left ventricular mass...
  18. ncbi Adipocyte-derived leucine aminopeptidase genotype and response to antihypertensive therapy
    Par Hallberg
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    BMC Cardiovasc Disord 3:11. 2003
    ..The enzyme seems to be particularly abundant in the heart. Recently, the Arg528-encoding allele of the ALAP gene was shown to be associated with essential hypertension...
  19. ncbi B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial
    Par Hallberg
    Department of Medical Sciences, Clinical Research Department 2, Uppsala University Hospital, 75185 Uppsala, Sweden
    J Hypertens 21:621-4. 2003
    ..We aimed to clarify whether the processes found in exercise-induced LV growth in normotensive people also occur in pathological LV hypertrophy...
  20. ncbi The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial
    Par Hallberg
    Department of Medical Sciences, Uppsala University, Uppsala, Sweden
    J Hypertens 20:2089-93. 2002
    ..However, its influence on clinical response to treatment with the AT(1) receptor antagonist, irbesartan, has not been investigated...
  21. ncbi Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study
    Fredrik Nyström
    Department of Medicine and Care, Faculty of Health Sciences, Linkoping, Sweden
    J Hypertens 20:1527-33. 2002
    ..To compare the relationships of treatment-induced reductions of left ventricular hypertrophy to the changes in clinic and ambulatory blood pressure (BP)...
  22. ncbi Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial
    Lisa Kurland
    Department of Internal Medicine, Uppsala University Hospital, Sweden
    Am J Hypertens 15:389-93. 2002
    ..Our aim was to determine whether the aldosterone synthase (CYP11B2) -344 C/T polymorphism was associated with the blood pressure (BP)-lowering response to antihypertensive treatment...
  23. ncbi Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (
    Lisa Kurland
    Department of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden
    J Hypertens 20:657-63. 2002
    ..Our aim was to determine if gene polymorphisms in the renin-angiotensin-aldosterone system (RAAS) were related to the degree of change in left ventricular hypertrophy (LVH) during antihypertensive treatment...
  24. ncbi Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA)
    Richard Müller-Brunotte
    Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden, and Department of Cardiology and Cardiovascular Surgery, School of Medicine, University of Navarra, Pamplona, Spain
    J Hypertens 25:1958-66. 2007
    ..This study examines myocardial fibrosis in relation to blood pressure, left ventricular mass (LVM), and diastolic function...
  25. ncbi Comparison of two immunochemical assays for measuring thrombin-activatable fibrinolysis inhibitor concentration with a functional assay in patients with acute coronary syndrome
    Mika Skeppholm
    Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiology, SE 182 88 Stockholm, Sweden
    Thromb Res 121:175-81. 2007
    ..Therefore the optimal choice of assay for determination of TAFI in different clinical studies is of importance. The Pefakit and Asserachrom seem to be appropriate candidates...